Please try another search
For the six months ended 30 September 2018, MPX Bioceutical Corp revenues increased from C$8.9M to C$29.1M. Net loss increased from C$2.9M to C$30.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects FV/Uls Adjust on Derivatives for Hedging decrease from C$101K (income) to C$10.1M (expense).
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Total Revenue | 14.67 | 14.46 | 7.98 | 4.48 |
Gross Profit | 4.41 | 3.07 | 1.83 | 1.55 |
Operating Income | -6.23 | -5.16 | -6.52 | -3 |
Net Income | -17.39 | -12.72 | -5.26 | -9.23 |
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Total Assets | 206.62 | 212.94 | 150.41 | 132.33 |
Total Liabilities | 130.12 | 119.8 | 75.1 | 67.9 |
Total Equity | 76.51 | 93.14 | 75.31 | 64.42 |
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Period Length: | 6 Months | 3 Months | 12 Months | 9 Months |
Cash From Operating Activities | -8.44 | -4.23 | -6.79 | -3.38 |
Cash From Investing Activities | -18.75 | -9.7 | -44.82 | -17.17 |
Cash From Financing Activities | 36.33 | 36.36 | 39.2 | 32.64 |
Net Change in Cash | 9.15 | 22.18 | -13.02 | 10.79 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review